CXCL17 is an allosteric inhibitor of CXCR4 through a mechanism of action involving glycosaminoglycans
Science Signaling · 2024
DOI: 10.1126/scisignal.abl3758 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Signaling, 2024. Verfasst von Carl W White und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cell Signalling and Pharmacology Research Group, Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottin…. Hauptthemen laut MEDLINE: Chemokines, CXC, Glycosaminoglycans. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council.
Abstract (Originalsprache)
CXCL17 is a chemokine principally expressed by mucosal tissues, where it facilitates chemotaxis of monocytes, dendritic cells, and macrophages and has antimicrobial properties. CXCL17 is also implicated in the pathology of inflammatory disorders and progression of several cancers, and its expression is increased during viral infections of the lung. However, the exact role of CXCL17 in health and disease requires further investigation, and there is a need for confirmed molecular targets mediating CXCL17 functional responses. Using a range of bioluminescence resonance energy transfer (BRET)–based assays, here we demonstrated that CXCL17 inhibited CXCR4-mediated signaling and ligand binding. Moreover, CXCL17 interacted with neuropillin-1, a VEGFR2 coreceptor. In addition, we found that CXCL17 only inhibited CXCR4 ligand binding in intact cells and demonstrated that this effect was mimicked by known glycosaminoglycan binders, surfen and protamine sulfate. Disruption of putative GAG binding domains in CXCL17 prevented CXCR4 binding. This indicated that CXCL17 inhibited CXCR4 by a mechanism of action that potentially required the presence of a glycosaminoglycan-containing accessory protein. Together, our results revealed that CXCL17 is an endogenous inhibitor of CXCR4 and represents the next step in our understanding of the function of CXCL17 and regulation of CXCR4 signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cell Signalling and Pharmacology Research Group, Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK.
- Centre of Membrane Proteins and Receptors, University of Birmingham and University of Nottingham, The Midlands, UK.
- Harry Perkins Institute of Medical Research and Centre for Medical Research, University of Western Australia, QEII Medical Centre, Nedlands, Western Australia 6009, Australia.
- Australian Research Council Centre for Personalised Therapeutics Technologies, Melbourne, Victoria, Australia.
- Dimerix Limited, Melbourne, Victoria, Australia.
- School of Pharmacy, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.
ORCID-Profile: Carl W White, Laura E Kilpatrick, Nicholas D Kindon, Barrie Kellam, Michael J Stocks, Kevin D G Pfleger, Stephen J Hill
Förderung
- Medical Research Council
Zitieren
APA
White, C. W., Platt, S., Kilpatrick, L. E., Dale, N., Abhayawardana, R. S., Dekkers, S., Kindon, N. D., Kellam, B., Stocks, M. J., Pfleger, K. D. G., & Hill, S. J. (2024). CXCL17 is an allosteric inhibitor of CXCR4 through a mechanism of action involving glycosaminoglycans. Science Signaling. https://doi.org/10.1126/scisignal.abl3758
Vancouver
White CW, Platt S, Kilpatrick LE, Dale N, Abhayawardana RS, Dekkers S, et al. CXCL17 is an allosteric inhibitor of CXCR4 through a mechanism of action involving glycosaminoglycans. Science Signaling. 2024. doi:10.1126/scisignal.abl3758
BibTeX
@article{White2024,
author = {White, Carl W and Platt, Simon and Kilpatrick, Laura E and Dale, Natasha and Abhayawardana, Rekhati S and Dekkers, Sebastian and Kindon, Nicholas D and Kellam, Barrie and Stocks, Michael J and Pfleger, Kevin D G and Hill, Stephen J},
title = {CXCL17 is an allosteric inhibitor of CXCR4 through a mechanism of action involving glycosaminoglycans},
journal = {Science Signaling},
year = {2024},
doi = {10.1126/scisignal.abl3758}
}
EUVIMED